OLFM2

Across TCGA pan-cancer cohorts, OLFM2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated OLFM2 data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher OLFM2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated OLFM2 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

LUAD, PDAC, and GBM are the cancer types where OLFM2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	All	0.270	0.823	.006	20	view →
PDAC	DFS	Tertile	II,III,IV	0.395	0.857	.029	6	view →
GBM	OS	Tertile	All	0.916	0.710	.027	4	view →
LSCC	DFS	Median	All	0.268	0.976	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

OLFM2–LUAD (OS)

Open the LUAD breakdown →